指南与共识外周血管介入心血管DSACTMR

经导管肾动脉去神经术治疗动脉高血压:法国高血压学会(SFHTA)、法国放射学会(SFR)、法国介入心脏病学会(GACI)、法国心脏病学会(SFC)、法国私人心脏病医师协会(CNCF)、法国医院心脏病医师协会(CNCH)、法国胸心血管外科学会(SFCTCV)与法国血管及腔内血管外科学会(SCVE)专家共识声明

Catheter-based renal denervation in the treatment of arterial hypertension: An expert consensus statement on behalf of the French Society of Hypertension (SFHTA), French Society of Radiology (SFR), French Society of Interventional Cardiology (GACI), French Society of Cardiology (SFC), French Association of Private Cardiologists (CNCF), French Association of Hospital Cardiologists (CNCH), French So
指南 / 共识 · Arch Cardiovasc Dis · 2024-09-12

多项高质量随机假手术对照试验支持射频、超声和酒精经导管肾动脉去神经术(RDN)降低血压的有效性和安全性;本法国共识提出RDN可作为确诊的难治性原发性高血压患者的辅助治疗,并给出适应证、术前评估、多学科团队验证、培训与注册登记等管理路径。

要点

  • RDN可作为经≥3种降压药(含长效CCB、RAS阻滞剂和噻嗪类/噻嗪样利尿剂)足量治疗后仍失控的难治性原发性高血压的辅助治疗。
  • 术前需满足eGFR≥40mL/min/1.73m²、肾动脉解剖适合RDN并排除继发性高血压。
  • RDN适应证应由高血压专家与腔内介入医师组成的多学科高血压团队在ESH卓越中心或ESH血压门诊验证。

核心结论

  • RDN可作为确诊的、经≥3种降压药(包括长效钙通道阻滞剂、肾素-血管紧张素系统阻滞剂和噻嗪类/噻嗪样利尿剂以最大耐受剂量)治疗后仍失控的难治性原发性高血压的辅助治疗;对难以控制的高血压患者可考虑其他适应证。

研究设计与样本

  • 法国专家共识文件,由法国高血压学会(SFHTA)、法国放射学会(SFR)、法国介入心脏病学会(GACI)、法国心脏病学会(SFC)、法国私人心脏病医师协会(CNCF)、法国医院心脏病医师协会(CNCH)、法国胸心血管外科学会(SFCTCV)与法国血管及腔内血管外科学会(SCVE)共同制定,基于多项高质量随机假手术对照试验的证据,提出RDN在高血压管理中的适用指南、专门护理路径和管理策略。

诊断标准与关键数值

  • RDN适用于确诊的、经≥3种降压药(包括长效钙通道阻滞剂、肾素-血管紧张素系统阻滞剂和噻嗪类/噻嗪样利尿剂以最大耐受剂量)治疗后仍失控的难治性原发性高血压患者。
  • 患者需满足:估算肾小球滤过率≥40mL/min/1.73m²;RDN术前扫描显示肾动脉解剖适合;排除继发性高血压。
  • 对难以控制的高血压患者可考虑其他适应证。
  • RDN适应证应由高血压专家和腔内介入医师组成的多学科高血压团队在欧洲高血压学会(ESH)卓越中心或ESH血压门诊验证。

临床应用与阅片要点

  • RDN适应证应由高血压专家和腔内介入医师组成的多学科高血压团队在ESH卓越中心或ESH血压门诊验证。
  • 应告知患者RDN的获益/风险比。
  • 实施RDN的腔内介入医师需具备肾动脉介入专长并接受RDN技术培训。
  • 提供RDN的中心应具备有效管理潜在并发症的必要资源。
  • 所有接受RDN的患者数据应收集于法国全国注册登记,以促进监测、评估RDN结局并支持持续研究和质量改进。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Several high-quality, randomized, sham-controlled trials have provided evidence supporting the efficacy and safety of radiofrequency, ultrasound and alcohol catheter-based renal denervation (RDN) for reducing blood pressure (BP). A French clinical consensus document has therefore been developed to propose guidance for the appropriate use of RDN in the management of hypertension along with a dedicated care pathway and management strategy. The French experts group concluded that RDN can serve as an adjunct therapy for patients with confirmed uncontrolled, resistant essential hypertension despite treatment with≥3 antihypertensive drugs, including a long-acting calcium channel blocker, a renin-angiotensin system blocker and a thiazide/thiazide-like diuretic at maximally tolerated doses. Patients should have (1) an estimated glomerular filtration rate of≥40mL/min/1.73m2; (2) an eligible renal artery anatomy on pre-RDN scans and (3) exclusion of secondary forms of hypertension. Additional indications might be considered for patients with difficult-to-control hypertension. Any indication of RDN should be validated by multidisciplinary hypertension teams consisting of both hypertension specialists and endovascular interventionalists in European Society of Hypertension (ESH) Excellence Centres or ESH-BP clinics. Patients should be informed about the benefit/risk ratio of RDN. Expertise in renal artery interventions and training in RDN techniques are needed for endovascular interventionalists conducting RDN procedures while centres offering RDN should have the necessary resources to manage potential complications effectively. Lastly, all patients undergoing RDN should have their data collected in a nationwide French registry to facilitate monitoring and evaluation of RDN outcomes, contributing to ongoing research and quality improvement efforts.

来源:Arch Cardiovasc Dis,查看原文。版权归原作者所有。

引用

  1. Pathak A, Boulestreau R, Sapoval M, et al. Catheter-based renal denervation in the treatment of arterial hypertension: An expert consensus statement on behalf of the French Society of Hypertension (SFHTA), French Society of Radiology (SFR), French Society of Interventional Cardiology (GACI), French Society of Cardiology (SFC), French Association of Private Cardiologists (CNCF), French Association of Hospital Cardiologists (CNCH), French Society of Thoracic and Cardiovascular Surgery (SFCTCV) and French Society of Vascular and Endovascular Surgery (SCVE). Arch Cardiovasc Dis. 2024. PMID: 39332916. doi:10.1016/j.acvd.2024.05.122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。